Tandem Diabetes Care is a medical devices business based in the US. Tandem Diabetes Care shares (TNDM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23.08 – a decrease of 0.22% over the previous week. Tandem Diabetes Care employs 2,650 staff and has a trailing 12-month revenue of around $983 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $23.08 |
|---|---|
| 52-week range | $15.75 - $53.69 |
| 50-day moving average | $19.19 |
| 200-day moving average | $31.87 |
| Wall St. target price | $34.86 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.79 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $23.08 from 2025-05-16
| 1 week (2025-05-12) | -1.58% |
|---|---|
| 1 month (2025-04-17) | 36.89% |
| 3 months (2025-02-20) | -28.14% |
| 6 months (2024-11-20) | -23.45% |
| 1 year (2024-05-20) | -51.13% |
|---|---|
| 2 years (2023-05-19) | -17.92% |
| 3 years (2022-05-19) | 72.99 |
| 5 years (2020-05-19) | 81 |
| Revenue TTM | $983 million |
|---|---|
| Gross profit TTM | $513.3 million |
| Return on assets TTM | -6.17% |
| Return on equity TTM | -92.31% |
| Profit margin | -18.71% |
| Book value | $2.33 |
| Market Capitalization | $1.5 billion |
TTM: trailing 12 months
We're not expecting Tandem Diabetes Care to pay a dividend over the next 12 months.
Tandem Diabetes Care's shares were split on a 1:10 basis on 9 October 2017 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tandem Diabetes Care shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Tandem Diabetes Care shares which in turn could have impacted Tandem Diabetes Care's share price.
Over the last 12 months, Tandem Diabetes Care's shares have ranged in value from as little as $15.7515 up to $53.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tandem Diabetes Care's is 1.483. This would suggest that Tandem Diabetes Care's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc.
We dug through 60 years of Berkshire Hathaway annual shareholder letters to bring you 9 lessons from Warren Buffett: “The Oracle of Omaha.”
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.
Here’s what you need to know about how to buy and sell stocks online in this easy to follow, step-by-step guide.